Comprehensive Management of Muscle-Invasive Bladder Cancer
Speaker: Prof. Antoine Van Der Heijden Affiliation: Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
[Academic In-depth Interpretation]
Editor’s Note: During the recent academic session, Professor Antoine Van Der Heijden from Radboud University Medical Center (Nijmegen, NL) shared comprehensive insights into the management of Muscle-Invasive Bladder Cancer (MIBC). The presentation focused on the clinical significance of histological subtypes, the inherent limitations of traditional Transurethral Resection of Bladder Tumor (TURBT), and the emerging value of MRI and Vi-RADS scoring in precision staging.
01 Histological Subtypes: Heterogeneity Dictates Therapeutic Sensitivity and Prognosis
Professor Van Der Heijden indicated that the core of primary MIBC evaluation lies in pathological confirmation. Currently, 13 histological subtypes of bladder cancer have been identified. Subtype analysis is not only prognostic but also directly informs therapeutic strategies. • Differential Responses to Neoadjuvant Chemotherapy (NAC): Research by Harrigan et al. (encompassing over 400 cases of pure urothelial carcinoma, 200 cases with squamous or glandular differentiation, and over 170 cases of variant histology) demonstrated that NAC improves survival outcomes in pure urothelial carcinoma and certain variant subtypes (e.g., micropapillary, plasmacytoid, and sarcomatoid). However, in patients with squamous or glandular differentiation, the survival benefit from NAC was not statistically significant. • Clinical Strategy: The professor emphasized that radical cystectomy remains the preferred treatment for pure squamous cell carcinoma and adenocarcinoma, whereas cisplatin-etoposide-based NAC is mandatory for neuroendocrine tumors.
02 Rethinking TURBT: Diagnostic Role and Risks of CTC Release
Although TURBT remains the “gold standard” for staging, its limitations are increasingly evident. • Staging Inaccuracies: Approximately 35%–40% of patients clinically staged as T1G3 are subsequently found to have muscle-invasive disease upon radical cystectomy. • Risk of CTC Release: A study by Englebertson (2015) showed that over 50% of patients had detectable Circulating Tumor Cells (CTCs) in the vena cava blood following TURBT. Furthermore, a 2017 study from China focusing on T3–T4 patients revealed that those diagnosed via TURBT had poorer outcomes compared to those diagnosed via simple biopsy, likely due to the hematogenous dissemination of tumor cells caused by surgical manipulation.
03 Imaging Revolution: The Role of Vi-RADS in Local Staging
Professor Van Der Heijden advocated for performing MRI prior to TURBT. • Vi-RADS Scoring System: This system integrates T2-weighted imaging (tissue structure), Diffusion-Weighted Imaging (cell density), and Dynamic Contrast-Enhanced imaging (vascular properties). o Vi-RADS 1–2: Muscle invasion is unlikely. o Vi-RADS 3: Equivocal. o Vi-RADS 4–5: Muscle invasion is likely or highly likely. • Clinical Significance: According to the UK “Bladder Path” trial, an MRI-guided diagnostic pathway significantly shortens the time from diagnosis to definitive treatment. For patients with Vi-RADS 4–5, clinicians may consider bypassing complex TURBT in favor of a cold-cup biopsy followed by definitive treatment (chemoradiation or cystectomy).
04 Distant Staging: Multimodal Imaging Comparison
For distant staging, CT, MRI, and PET/CT each have distinct roles. • CT vs. MRI: CT is widely available with high spatial resolution but is limited in distinguishing between T1 and T3a stages. MRI is valuable for patients with contrast allergies but is inferior to CT for upper urinary tract evaluation. • Superiority of PET/CT: A Dutch nationwide cohort study showed that PET/CT increased the detection rate of lymph node metastases to 36%, compared to 10% for CT. In a sample of 700 patients from Amsterdam UMC, 26% underwent upstaging due to PET/CT findings, leading to a change in treatment plans for 18% of the cohort (with approximately half shifting from curative to palliative intent).
05 Conclusion and Clinical Recommendations
Professor Van Der Heijden concluded with several take-home messages for MIBC management:
- Prioritize Subtyping: Identifying subtypes such as micropapillary, sarcomatoid, and plasmacytoid is crucial for identifying patients likely to benefit from NAC.
- MRI Pre-TURBT: MRI should ideally be performed before TURBT to assess muscle invasion risk using the Vi-RADS score.
- Multimodal Staging: Routine contrast-enhanced CT of the chest and abdomen (including an excretory phase) remains necessary. PET/CT offers higher sensitivity for lymph node and distant metastasis assessment, potentially preventing unnecessary radical surgeries.
